Hasten Biopharmaceutical buys asset rights for 14 branded products from Celltrion
In a significant move, CBC Group, Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its portfolio company, Hasten Biopharmaceutical, has successfully acquired the asset rights of 14 branded products from South Korean biopharmaceutical company, Celltrion. The deal price remains undisclosed. According to the agreement, Hasten Biopharmaceutical will hold the Marketing Authorization Holder […]